Adalid specializes in developing lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics (Hejdankova & Vanek, Adv. Funct. Mater. 2021). Our scientists have synthesized over 150 novel ionizable lipidoids, conducted biophysical characterizations of their LNPs, and evaluated their efficacy in various in vivo models.

 

These evaluations assess the potency and safety of the LNPs for delivering nucleic acids such as siRNA, mRNA, DNA plasmids, and miRNA. We have demonstrated that the ionizable lipidoid component is crucial in determining the potency of LNP therapeutics. Our discovery and development programs are ongoing, with a focus on surpassing the in vivo efficacy and targetability of our novel LNPs.